Skip to content

Study · Randomized controlled trial · n = 93 · 2009

5 results

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C

Obesity (Silver Spring, Md.)11 Jun 2009Cited by 233 (Europe PMC)

PMID19521351 (opens in a new tab)PMCIDPMC2754219 (opens in a new tab)DOI10.1038/oby.2009.184 (opens in a new tab)PepBankPUB-19521351
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese subjects, adding pramlintide to metreleptin reduced weight more than metreleptin alone.

    In plain wordsIn overweight or obese people, adding pramlintide to metreleptin reduced weight more than metreleptin alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCombination weight loss versus metreleptin
    Study

    n = 93

    Comparator
    Metreleptin alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    360 microg b.i.d. · 20 weeks after 4-week lead-inAs given in this study (human).

    Measurements

    Weight change
    −12.7%
    combination
    Weight change
    −8.2%
    metreleptin alone

    Source sentences

    Summary
    Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9%; least squares mean +/- s.e.) than treatment with pramlintide (-8.4 +/- 0.9%; P < 0.001) or metreleptin (-8.2 +/- 1.3%; P < 0.01) alone (evaluable, N = 93).
    2 context sentences
    Summary · context
    To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept study was conducted in obese or overweight subjects (N = 177; 63% female; 39 +/- 8 years; BMI 32.0 +…
    Summary · context
    After a 4-week lead-in period with pramlintide (180 microg b.i.d. for 2 weeks, 360 microg b.i.d. thereafter) and diet (40% calorie deficit), subjects achieving 2-8% weight loss were randomized 1:2:2 to 20 weeks of treatment with metreleptin (5 mg b.i.d.), pramlintide (360 microg b.i.d.), or pramlint…

Studies that did not test the peptide alone4

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In overweight or obese subjects, pramlintide/metreleptin reduced weight more than pramlintide alone.

    In plain wordsIn overweight or obese people, the pramlintide/metreleptin combination reduced weight more than pramlintide alone.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCombination weight loss versus pramlintide
    Study

    n = 93

    Comparator
    Pramlintide alone
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −12.7%
    combination
    Weight change
    −8.4%
    pramlintide alone

    Source sentences

    Summary
    Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9%; least squares mean +/- s.e.) than treatment with pramlintide (-8.4 +/- 0.9%; P < 0.001) or metreleptin (-8.2 +/- 1.3%; P < 0.01) alone (evaluable, N = 93).
    2 context sentences
    Summary · context
    To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept study was conducted in obese or overweight subjects (N = 177; 63% female; 39 +/- 8 years; BMI 32.0 +…
    Summary · context
    After a 4-week lead-in period with pramlintide (180 microg b.i.d. for 2 weeks, 360 microg b.i.d. thereafter) and diet (40% calorie deficit), subjects achieving 2-8% weight loss were randomized 1:2:2 to 20 weeks of treatment with metreleptin (5 mg b.i.d.), pramlintide (360 microg b.i.d.), or pramlint…

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome

    In overweight or obese subjects, greater combination weight loss appeared by week 4 and continued without a plateau.

    In plain wordsIn overweight or obese people, combination weight loss exceeded monotherapies by week 4 and continued without a plateau.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseCombination weight loss trajectory
    Study

    n: not reported in source

    Comparator
    Monotherapies
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The greater reduction in body weight was significant as early as week 4, and weight loss continued throughout the study, without evidence of a plateau.
    3 context sentences
    Summary · context
    Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9%; least squares mean +/- s.e.) than treatment with pramlintide (-8.4 +/- 0.9%; P < 0.001) or metreleptin (-8.2 +/- 1.3%; P < 0.01) alone (evaluable, N = 93).
    Summary · context
    To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept study was conducted in obese or overweight subjects (N = 177; 63% female; 39 +/- 8 years; BMI 32.0 +…
    Summary · context
    After a 4-week lead-in period with pramlintide (180 microg b.i.d. for 2 weeks, 360 microg b.i.d. thereafter) and diet (40% calorie deficit), subjects achieving 2-8% weight loss were randomized 1:2:2 to 20 weeks of treatment with metreleptin (5 mg b.i.d.), pramlintide (360 microg b.i.d.), or pramlint…

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  3. 04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome

    In overweight or obese subjects, injection site events were common with pramlintide/metreleptin, mostly mild to moderate, and decreased over time.

    In plain wordsIn overweight or obese people, injection site events were common with the combination treatment, mostly mild to moderate, and decreased over time.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableInjection site events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    The most common adverse events with pramlintide/metreleptin were injection site events and nausea, which were mostly mild to moderate and decreased over time.
    2 context sentences
    Summary · context
    To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept study was conducted in obese or overweight subjects (N = 177; 63% female; 39 +/- 8 years; BMI 32.0 +…
    Summary · context
    After a 4-week lead-in period with pramlintide (180 microg b.i.d. for 2 weeks, 360 microg b.i.d. thereafter) and diet (40% calorie deficit), subjects achieving 2-8% weight loss were randomized 1:2:2 to 20 weeks of treatment with metreleptin (5 mg b.i.d.), pramlintide (360 microg b.i.d.), or pramlint…

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  4. 05HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome

    In overweight or obese subjects, nausea was common with pramlintide/metreleptin, mostly mild to moderate, and decreased over time.

    In plain wordsIn overweight or obese people, nausea was common with the combination treatment, mostly mild to moderate, and decreased over time.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    The most common adverse events with pramlintide/metreleptin were injection site events and nausea, which were mostly mild to moderate and decreased over time.
    2 context sentences
    Summary · context
    To evaluate the weight-lowering effect of combined amylin/leptin agonism (with pramlintide/metreleptin) in human obesity, a 24-week, randomized, double-blind, active-drug-controlled, proof-of-concept study was conducted in obese or overweight subjects (N = 177; 63% female; 39 +/- 8 years; BMI 32.0 +…
    Summary · context
    After a 4-week lead-in period with pramlintide (180 microg b.i.d. for 2 weeks, 360 microg b.i.d. thereafter) and diet (40% calorie deficit), subjects achieving 2-8% weight loss were randomized 1:2:2 to 20 weeks of treatment with metreleptin (5 mg b.i.d.), pramlintide (360 microg b.i.d.), or pramlint…

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.